报告题目：Analytical method development and application for heparins
报 告 人：欧阳艺兰 （苏州大学）
Yilan Ouyang, a ph.D candidate, majored in pharmaceutical analysis. She was enrolled in Soochow University as a graduate student in 2013. She had one year study experience in Rensselaer Polytechnic Institute as an exchanging student in 2017-2018. She focused on the glycomics of heparin in Soochow University. In graduate career, she developed a series of advanced, effective and comprehensive analytical methods to analyze heparins, such as Mw determination, compositional analysis and fingerprinting analysis. She also applied those methods to compare heparins from different processes, sources and times. The results provide clues for good quality control and optimization of processes for heparins. In addition, the developed analytical platform was critical for her to develop a new product called non-anticoagulant heparins by chemical modification.
Heparin is a mixture of sulfated linear polysaccharides with repeating disaccharide unit, which has dispersity of molecular weight (MW) and micro-heterogenous structural composition with multiple sequences. Additionally, various characterization of structures obtained from extraction sources and production processes. There have been concerns on the safety and security of the heparin supply chain since 2007-2008 when a contamination crisis led to its disruption. Thus, the characterization of structures and sequences of heparin drugs is challenging and urgent. A series of advanced and effective analytical methods for heparins were developed, such as Mw determination, compositional analysis and fingerprinting analysis, coupled with chemometric analysis could effectively use to quality control of heparin. There have been a number of studies aimed at developing heparin-based therapeutics by removing heparin’s prominent anticoagulant activity to obtain non-anticoagulant heparin (NACH). In study, comprehensive structural analysis and pharmaceutical applications for NACHs were studied to promote expansion of new indication for heparin-based products.